New benzimidazole-triazole glycoconjugates as anti-cancer agents and EGFR inhibitors.

Such hybrid molecules, with their reported potent anticancer and enzyme inhibition activity, comprise various linkage types of the heterocyclic core to the sugar moiety, which may be significant in enzymatic interactions, leading to promising anticancer effects, particularly on breast cancer cell lines.

also in 13,097 other papers